ArticleScientific reports2025
Expression and diagnostic value evaluation of urinary exosomal miR-142-3p in diabetic nephropathy.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic value of urinary exosomes in patients with IgA nephropathy and diabetic kidney disease: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Urinary Extracellular Vesicle-Derived miRNAs as Regulators and Biomarkers in Diabetic Kidney Disease.International journal of molecular sciences · 2026Review
- From pathogenic carriers to therapeutic hope: the dual role and translational prospects of exosomes in diabetic kidney disease.Frontiers in endocrinology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic nephropathy (DN) is one of the most severe microvascular complications of diabetes mellitus and a common cause of end-stage renal disease. Although kidney biopsy is the gold standard for diagnosing DN, it carries risks of complications such as infection and bleeding. Urinary microalbumin is currently used as a clinical indicator for diagnosing DN, but its early predictive ability is limited. Therefore, identifying non-invasive biomarkers for diagnosing DN has become a recent research focus. This study aimed to screen and identify differentially expressed miRNAs in diabetes and DN and evaluate their clinical diagnostic value to provide new directions for DN diagnosis. This study included 42 patients with diabetes and 57 patients with DN. Differentially expressed miRNAs in DN and type 2 diabetes mellitus were screened using the GEO database. General clinical data and urine samples were collected from both groups of patients. Urinary exosomes were extracted using ultracentrifugation, and qRT-PCR was used to detect changes in urinary exosomal miRNA expression between the two groups of patients. Receiver operating characteristic (ROC) curve analysis and Spearman correlation analysis were performed to evaluate the clinical diagnostic value of miRNAs. Urinary exosomal miR-142-3p was upregulated in DN patients compared to T2DM patients. ROC curve analysis showed that miR-142-3p had good diagnostic value for the disease and was positively correlated with UACR and risk stratification indicators for the progression of chronic kidney disease. Additionally, KEGG enrichment analysis revealed that urinary exosomal miR-142-3p may be involved in disease progression through pathways such as fatty acid metabolism, fatty acid biosynthesis, Hippo signaling pathway, cGMP-PKG signaling pathway, and Wnt signaling pathway. These results suggest that urinary exosomal miR-142-3p has good diagnostic performance in DN and may serve as a potential biomarker for diagnosing DN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.